Melanocortin-4 receptor (MC4R) agonist
Setmelanotide
Brand names: Imcivree
Adult dose
Dose: Initial 2mg SC OD, titrate to 3mg OD per BNF/SmPC
Route: SC
Frequency: OD
Clinical pearls
- Genetic obesity due to POMC, PCSK1 or LEPR deficiency, BBS
- Specialist obesity service
Contraindications
- Pregnancy/breastfeeding
- Hypersensitivity
Side effects
- Injection-site reactions
- Hyperpigmentation
- Spontaneous penile erection
- Nausea
- Hypersensitivity
- Depression
Monitoring
- Skin
- Mood
- Weight
Reference: BNF; NICE TA919; SmPC; https://bnf.nice.org.uk/drugs/setmelanotide/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
- Pituitary Apoplexy · ENEA 2011 / Pituitary Society
- Hypercalcaemia Management · NICE / Endocrine Society